Ratings Sartorius Stedim Biotech OTC Markets

Equities

SDMHF

FR0013154002

Market Closed - OTC Markets Other stock markets 02:46:14 2024-07-09 pm EDT			5-day change	1st Jan Change
176.2 ^USD	+0.69%		0.00%	-33.19%

Jul. 10	Markets Powered by Alternating Current
Jul. 09	Mixed feelings

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

One of the major weak points of the company is its financial situation.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 52.26 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SARTORIUS STEDIM BIOTECH	-33.19%	18.45B	-
ABBOTT LABORATORIES	-4.90%	182B	C+
MEDTRONIC PLC	-1.36%	104B	C
DEXCOM, INC.	-7.64%	45.58B	B-
HOYA CORPORATION	+9.30%	46.44B	B+
CENCORA, INC.	+9.63%	44.34B	B-
METTLER-TOLEDO INTERNATIONAL, INC.	+13.63%	29.44B	B
TERUMO CORPORATION	+20.29%	26.8B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-7.12%	23.82B	A-
STERIS PLC	+4.03%	22.61B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes